Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Godfrey

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
The Lancet. Global Health|September 21, 2023
Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysisAndrew N Phillips, Loveleen Bansi-Matharu, Maryam Shahmanesh, et al.
Pharmacogenetics and Genomics|February 28, 2020
Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptivesDavid W Haas, Yoninah S Cramer, Catherine Godfrey, et al.
The Journal of Infectious Diseases|June 16, 2007
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211Roy M Gulick, Zhaohui Su, Charles Flexner, et al.
The Lancet. HIV|February 28, 2024
Centring the health of women across the HIV research continuumElizabeth Barr, Leslie J Marshall, Lauren F Collins, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 9, 2020
Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early ChemotherapyMulinda Nyirenda, McNeil Ngongondo, Minhee Kang, et al.
Plos Pathogens|April 21, 2017
Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activationRajesh T Gandhi, Deborah K McMahon, Ronald J Bosch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 17, 2018
A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298Timothy J Wilkin, Huichao Chen, Michelle S Cespedes, et al.
The Journal of Infectious Diseases|August 16, 2021
A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral TherapyDeborah K McMahon, Lu Zheng, Joshua C Cyktor, et al.
The Journal of Infectious Diseases|October 31, 2024
Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women With HIVNicole H Tobin, Sarah L Brooker, Fan Li, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 13, 2020
Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral TherapyCatherine Godfrey, Michael D Hughes, Justin Ritz, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
The Lancet. Global Health|September 21, 2023
Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysisAndrew N Phillips, Loveleen Bansi-Matharu, Maryam Shahmanesh, et al.
Pharmacogenetics and Genomics|February 28, 2020
Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptivesDavid W Haas, Yoninah S Cramer, Catherine Godfrey, et al.
The Journal of Infectious Diseases|June 16, 2007
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211Roy M Gulick, Zhaohui Su, Charles Flexner, et al.
The Lancet. HIV|February 28, 2024
Centring the health of women across the HIV research continuumElizabeth Barr, Leslie J Marshall, Lauren F Collins, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 9, 2020
Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early ChemotherapyMulinda Nyirenda, McNeil Ngongondo, Minhee Kang, et al.
Plos Pathogens|April 21, 2017
Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activationRajesh T Gandhi, Deborah K McMahon, Ronald J Bosch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 17, 2018
A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298Timothy J Wilkin, Huichao Chen, Michelle S Cespedes, et al.
The Journal of Infectious Diseases|August 16, 2021
A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral TherapyDeborah K McMahon, Lu Zheng, Joshua C Cyktor, et al.
The Journal of Infectious Diseases|October 31, 2024
Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women With HIVNicole H Tobin, Sarah L Brooker, Fan Li, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 13, 2020
Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral TherapyCatherine Godfrey, Michael D Hughes, Justin Ritz, et al.
Pageof 11